Tuesday Mar 4
Shire plc To Present At The Cowen and Company 34th Annual Health Care Conference
Shire's Chief Executive Officer, Flemming Ornskov, MD will present at the Cowen and Company 34th Annual Health Care Conference today, March 4th at 08:00 AM EST/13:00 GMT.
Trending on the Topix Network
Tuesday Mar 4
Elections for Interim Dividend in Respect of the Six Months to December 31, 2013
Shareholders who do not elect to receive sourced dividends through the income access share arrangements are reminded that their dividends will be Irish sourced and subject to Irish dividend withholding tax unless the Company's Registrar is in possession of a valid exemption form by .
Thu Feb 27, 2014
Shire Recognizes Rare Disease Day 2014
Shire plc today announced its support of Rare Disease Day and invites others to join them in its continued commitment to the rare disease community.
New Phase 3 Data For Guanfacine Extended Release (GXR) To Be Presented At
February 27, 2014 - Shire plc today announced that scientific data from two of its guanfacine extended release European pivotal Phase 3 clinical studies are being presented at the 22nd European Congress of Psychiatry in Munich, Germany, March 1-4.
Wed Feb 26, 2014
Dyax's new long-lasting HAE drug shows early promise
Dyax Corp . shares were trading up this morning following positive Phase 1 data for its new drug candidate to prevent attacks for patients with the rare disease, hereditary angioedema.
Mon Feb 24, 2014
Shire PLC - 10-K - : Management's discussion and analysis of...
The following discussion should be read in conjunction with the Company's consolidated financial statements contained in Part IV in this Annual Report on Form 10-K.
Fri Feb 21, 2014
Shire Chairman sells shares following 'excellent' 2013 results
Shire's Chairman, Matthew Emmens, has sold 36,100 shares in the biopharmaceutical company following its 'excellent' results for 2013.
Wed Feb 19, 2014
Shire plc Submits Elvanse (Lisdexamfetamine Dimesylate) For...
February 19, 2014 - Shire plc today announced the acceptance for review of an application for an adult indication, for their once-daily Attention Deficit/Hyperactivity Disorder medication ElvanseA , for newly diagnosed adult patients.
Tue Feb 18, 2014
Shire PLC's "Buy" Rating Reaffirmed at Jefferies Group
's stock had its "buy" rating reaffirmed by equities researchers at Jefferies Group in a research report issued on Tuesday, AmericanBankingNews.com reports.
NASDAQ Gainers Watch List: Plug Power Inc. (NASDAQ:PLUG) and Shire...
Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Plug Power Inc. and Shire plc .
Mon Feb 17, 2014
Shire PLC Rating Reiterated by Cenkos Securities Ltd
's stock had its "buy" rating reaffirmed by research analysts at Cenkos Securities Ltd in a report released on Monday, StockRatingsNetwork reports.
Fri Feb 14, 2014
The Motley Fool
Why Did Billionaire Mario Gabelli's Company Buy Diebold, Responsys, and ViroPharma?
The latest 13F season is commencing, when many money managers issue required reports on their holdings.
Shire facility in Lexington gets FDA approval to manufacture Gaucher disease drug
Shire plc , an Irish drug company with about 1,400 employees at its Lexington research campus, said Friday that it has gotten US regulatory approval to make the Gaucher disease drug Vpriv at its Lexington manufacturing facility.
Shire Announces FDA Approval of Manufacturing Facility for VPRIVA ...
Shire plc , the global specialty biopharmaceutical company, announced today that the US Food & Drug Administration has approved the production of VPRIVA drug substance in Shire's manufacturing facility at 400 Shire Way, provides greater assurance that Gaucher patients will receive consistent and uninterrupted access to enzyme replacement therapy ... (more)
Thu Feb 13, 2014
FTSE 100 movers: Rolls-Royce nosedives on 2014 outlook
Rolls-Royce's shares tumbled after the group said it expects flat 2014 revenue and profit due to cuts in government defence spending.
Shire beats forecasts with strong Q4, CFO steps down
Shire has said that Chief Financial Officer Graham Hetherington is to step down as of next month, as the company revealed 'excellent' results for 2013 which after a pick-up in earnings growth in the fourth quarter beat forecasts.
Shire PLC (SHP) - Research Analysts' Recent Ratings Updates
Shire PLC had its "outperform" rating reaffirmed by analysts at BNP Paribas. They now have a GBX 3,100 price target on the stock.
Fri Feb 07, 2014
Shire PLC: Time to Panic?
Shire PLC is a Dublin-based biopharmaceutical company that operates in Ireland, the UK, North America and the rest of the world.
The Motley Fool
Why You Should Watch Ariad Pharmaceuticals, Cigna Corporation and Shire plc Today
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.